Recursion Pharmaceuticals Inc
NASDAQ:RXRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
US |
|
La Francaise de l Energie SA
F:LFX
|
FR |
Intrinsic Value
The intrinsic value of Recursion Pharmaceuticals Inc (RXRX) under the Base Case is 1.383 USD per share.
Compared with the current market price of 3.885 USD, the stock appears
Overvalued by 64% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Recursion Pharmaceuticals Does
Recursion Pharmaceuticals is a drug discovery company that uses automation, large-scale biological experiments, and software to find new medicines faster. It builds a digital map of cells and uses that data to spot how diseases behave and which compounds might change them. The company mainly sells research partnerships and also develops its own drug candidates.
- Headquarters
- United States of America US
- Employees
- 600
- IPO date
- Apr 16, 2021
Recursion Pharmaceuticals has no economic moat
Recursion Pharmaceuticals Inc lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysis
Earnings Waterfall
Recursion Pharmaceuticals Inc
The intrinsic value for Recursion Pharmaceuticals Inc (RXRX) under the Base Case is 1.383 USD.
Compared with the current market price of 3.885 USD, the stock appears Overvalued by 64% .
